Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

Abramson, Beth L; Benlian, Pascale; Hanson, Mary E; Lin, Jianxin; Shah, Arvind; Tershakovec, Andrew M

doi:10.1186/1476-511X-10-146

Lipids in Health and Disease

Table 1 Characteristics of studies included in the pooled analyses

From: Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

Protocol Number [citation]	Treatment	Randomized to Statin		Randomized to Statin+EZ		Inclusion Criteria
		Men (N = 5389)	Women (N = 5142)	Men (N = 6140)	Women (N = 5607)	Min LDL-C	Max LDL-C
005 [37]	PBO, EZ EZ+S 10, 20, 40, 80 S 10, 20, 40, 80	172	177	169	184	145 mg/dL	250 mg/dL
011 [38]	PBO, EZ S 10, 20, 40, 80 EZ+S 10, 20, 40, 80	110	153	126	148	145 mg/dL	250 mg/dL
021 [15]	S 20 + EZ Doubling S to 40	61	49	62	42	101 mg/dL	not specified
023 [25]	S 20, EZ+S 10, 20, 40	158	95	292	165	130 mg/dL	not specified
025 [39]	A 10 EZ + S 10, 20	131	131	279	247	not at LDL-C goal as defined by NCEP ATP III
030 [40]	A 10 + EZ Doubling A to 20	171	145	159	146	130 mg/dL	not specified
038 [11]	PBO, EZ EZ/S 10, 20, 40, 80 S 10, 20, 40, 80	307	315	296	313	145 mg/dL	250 mg/dL
040 [18]	Ongoing statin + PBO Ongoing statin + EZ	510	500	1073	947	not at LDL-C goal as defined by NCEP ATP III
051 [41]	EZ/S 10, 20, 40, 80 A 10, 20, 40, 80	498	453	496	455	not at LDL-C goal as defined by NCEP ATP III
058 [42]	EZ/S 10, 20, 40, 80 R 10, 20, 40	624	857	678	800	145 mg/dL	250 mg/dL
077 [43]	EZ/S 20, 40 A 10, 20, 40	361	374	221	273	100 mg/dL	not specified
079 [12]	A 20 + EZ Doubling to A 40	49	49	58	40	100 mg/dL	160 mg/dL
090 [16]	A 40 + EZ Doubling to A 80	178	113	173	115	70 mg/dL	160 mg/dL
107 [20]	EZ/S 20, 40 A 10, 20, 40	379	307	266	191	70 mg/dL 100 mg/dL	not specified
112 [22]	A 10 + EZ A 20/40	249	277	241	286	70 mg/dL 100 mg/dL	160 mg/dL
679 [44]	PBO, EZ L 10, 20, 40 EZ+L 10, 20, 40	88	132	86	106	145 mg/dL	250 mg/dL
691 [17]	PBO, EZ P 10, 20, 40 EZ+P 10, 20, 40	101	104	83	121	145 mg/dL	250 mg/dL
692 [45]	PBO, EZ A 10, 20, 40, 80 EZ+A 10, 20, 40, 80	95	153	107	148	145 mg/dL	250 mg/dL
700 [46]	S 20 + EZ Double S to 40	19	15	33	33	130 mg/dL	not specified
801 [23]	S 10, 20 + PBO S 10, 20 + EZ	158	52	145	63	101 mg/dL	160 mg/dL
802 [47]	S 10, 20 + PBO S 10, 20 + EZ	124	57	124	57	101 mg/dL	160 mg/dL
803/804 [24]	A 10, 20 + PBO A 10, 20 + EZ	157	73	153	67	101 mg/dL	160 mg/dL
806 [48]	EZ/S 20 Doubling to A 20	128	86	141	80	101 mg/dL	160 mg/dL
807 [49]	EZ/S 20, 40 Doubling to A 20	108	111	224	218	not specified	not specified
809 [13]	EZ/S 20 R10	185	119	185	129	100 mg/dL	160 mg/dL
2173/2246 [14]	Ongoing statin + EZ Ongoing statin+ PBO	221	169	222	157	not at LDL-C goal as defined by NCEP ATP III
3377 [21]	EZ+S 20 S 20	47	76	48	76	145 mg/dL	250 mg/dL

A = atorvastatin; EZ = ezetimibe; L = lovastatin; LDL-C = low-density lipoprotein cholesterolemia; NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel III; P = pravastatin = S = simvastatin.

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com